University of Wisconsin Carbone Cancer Center | Strategic Alliance Partners

Latest from University of Wisconsin Carbone Cancer Center


The Prostate Cancer Paradox Revisited

September 25, 2019

Conflicting guidelines on prostate-specific antigen testing have affected trends on disease presentation and, potentially, the treatment outcomes for many men with this disease. New agents and powerful new imaging tools have added yet more complexity to the decision process. Therefore, more investigation and cooperation on multiple levels is needed to define appropriate standards of care.

Dr. O'Regan on Future of Chemotherapy in Breast Cancer

December 11, 2018

Ruth O’Regan, MD, division head, Hematology and Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, discusses the role of chemotherapy as treatment continues to advance in breast cancer.

Dr. O'Regan on Impact of Targeted Agents in HER2+ Breast Cancer

November 22, 2018

Ruth O’Regan, MD, division head, Hematology and Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, discusses the impact of targeted agents in HER2-positive breast cancer.

CLR 131 Found to Broadly Target Pediatric Solid Tumors

September 16, 2017

According to a new study by UW Carbone Cancer Center researchers, a broadly applicable cancer therapy currently being developed by Cellectar Biosciences may have the potential to work in pediatric solid tumors.

Dr. O'Regan Discusses the Future of Treatment in HER2+ Breast Cancer

May 16, 2017

Ruth O’Regan, MD, division head of Hematology and Oncology in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health, discusses the potential of future treatments for patients with HER2-positive breast cancer.

x